<div id="readability-page-1"><p>Prudential Financial Inc. grew its stake in shares of  Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 178.4% during the 2nd quarter, according to the company in its most recent filing with the Securities &amp; Exchange Commission. The institutional investor  owned 37,118 shares of the biotechnology company's stock after acquiring an additional 23,785 shares during the period. Prudential Financial Inc.'s holdings in Veracyte were worth $1,003,000 as of its most recent SEC filing.</p><p>A number of other hedge funds have also modified their holdings of the stock. Blair William &amp; Co. IL boosted its position in  Veracyte by 3.5% during the first quarter. Blair William &amp; Co. IL now owns 16,092 shares of the biotechnology company's stock valued at $477,000 after purchasing an additional 550 shares during the last quarter.  Vanguard Group Inc. raised its stake in shares of  Veracyte by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 8,263,643 shares of the biotechnology company's stock worth $245,017,000 after purchasing an additional 52,031 shares in the last quarter.  Charles Schwab Investment Management Inc. raised its stake in shares of  Veracyte by 2.7% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 740,631 shares of the biotechnology company's stock worth $21,960,000 after purchasing an additional 19,662 shares in the last quarter.  Headlands Technologies LLC acquired a new stake in shares of  Veracyte during the 1st quarter valued at about $48,000.  Finally, Covestor Ltd grew its stake in shares of  Veracyte by 23,936.4% in the 1st quarter. Covestor Ltd now owns 2,644 shares of the biotechnology company's stock valued at $78,000 after buying an additional 2,633 shares in the last quarter. </p><h2>Analyst Ratings Changes</h2><p>Several equities analysts recently weighed in on VCYT shares. UBS Group raised their price objective on shares of Veracyte from $42.00 to $48.00 and gave the company a &#34;buy&#34; rating in a research report on Wednesday, November 5th. Wall Street Zen upgraded shares of Veracyte from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research note on Sunday, November 16th. Canaccord Genuity Group lifted their price objective on shares of Veracyte from $40.00 to $43.00 and gave the company a &#34;hold&#34; rating in a research note on Wednesday, November 5th. Morgan Stanley upped their price objective on shares of Veracyte from $40.00 to $48.00 and gave the stock an &#34;underweight&#34; rating in a report on Monday, December 1st. Finally, Guggenheim raised their target price on Veracyte from $40.00 to $45.00 and gave the company a &#34;buy&#34; rating in a report on Wednesday, November 5th. One investment analyst  has rated the stock with a Strong Buy rating, five have issued  a Buy rating, two have assigned  a Hold rating and one  has assigned  a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $45.43.</p><p><b>Check Out Our Latest Stock Report on VCYT</b></p><h2>Veracyte Stock Down 5.9%</h2><p>NASDAQ:VCYT opened at $44.61 on Monday. The company's 50 day moving average is $39.33 and its 200-day moving average is $32.04. Veracyte, Inc. has a 12 month low of $22.61 and a 12 month high of $50.71. The firm has a market cap of $3.53 billion, a price-to-earnings ratio of 117.40 and a beta of 1.82. </p><p>Veracyte (NASDAQ:VCYT - Get Free Report) last posted its earnings results on Tuesday, November 4th. The biotechnology company reported $0.51 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.32 by $0.19. The business had revenue of $131.87 million for the quarter, compared to analyst estimates of $124.62 million. Veracyte had a net margin of 6.12% and a return on equity of 7.23%. Veracyte's revenue was up 13.8% compared to the same quarter last year. During the same period last year, the business posted $0.33 EPS.  Research analysts predict that  Veracyte, Inc. will post 0.68 EPS for the current fiscal year. </p><h2>Insider Activity at Veracyte</h2><p>In other news, SVP Annie Mcguire sold 1,422 shares of Veracyte stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $47.30, for a total value of $67,260.60. Following the transaction, the senior vice president directly owned 78,499 shares in the company, valued at approximately $3,713,002.70. The trade was a 1.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Evan/ Fa Jones sold 1,106 shares of the stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $50.25, for a total value of $55,576.50. Following the sale, the director owned 29,362 shares of the company's stock, valued at approximately $1,475,440.50. The trade was a 3.63% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 114,528 shares of company stock valued at $4,987,433. 1.40% of the stock is owned by corporate insiders. </p><h2>Veracyte Company Profile</h2> (Free Report)<p>Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.</p><h2>Read More</h2><ul><li>Five stocks we like better than Veracyte</li><li>What is the Hang Seng index?  </li><li>Rubrik’s Massive Rebound: Why the Next Leg Higher Could Be Fast</li><li>Why Special Dividends Can be a Delightful Surprise for Income Investors</li><li>Five Below and Dollar Tree Earnings Signal a Shopper Shift</li><li>What is a support level?</li><li>Ulta’s Stock May Be Set for a Glow-Up—20% Upside Ahead?</li></ul><p><strong>Want to see what other hedge funds are holding VCYT?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Veracyte, Inc. (NASDAQ:VCYT - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VkNZVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VkNZVA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Veracyte Right Now?</h2><p>Before you consider Veracyte, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veracyte wasn't on the list.</p><p>While Veracyte currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

VCYT

<p>Prudential Financial Inc. increased its stake in Veracyte, Inc. by 178.4% in Q2, owning 37,118 shares worth $1 million. Analysts have adjusted ratings and price targets for Veracyte, with a consensus rating of "Moderate Buy" and a target price of $45.43. Veracyte's stock opened at $44.61, with a market cap of $3.53 billion.</p>

Prudential Financial Inc. Has $1 Million Position in Veracyte, Inc. $VCYT